AHA Scientific Sessions 2026 Abstract · Nov 2, 2026
Renin-Guided Risk Stratification and Therapy in Hypertension to Reduce Major Adverse Cardiovascular Outcomes
By Tsai CH, Chang YC, Brown JM et al.
Background: Hypertension is a heterogeneous disorder, and blood pressure level alone may not adequately capture the underlying pathophysiology or guide optimal treatment selection. Plasma renin activity is widely used to screen for primary aldosteronism, but its broader role in cardiovascular risk stratification and mechanism-based antihypertensive therapy remains incompletely defined. Hypothesis: We hypothesized that plasma renin activity identifies biologically distinct hypertensive phenotypes associated with differential long-term cardiovascular risk and treatment responsiveness. Specifically, we examined whether suppressed renin identifies patients who may preferentially benefit from mineralocorticoid receptor antagonist (MRA) therapy, whereas elevated renin identifies patients more likely to benefit from renin-angiotensin system inhibition. Methods: In this multicenter retrospective cohort of 16,600 people with hypertension, we evaluated the association between plasma renin activity and major adverse cardiovascular events (MACE) defined as stroke, myocardial infarction, and all-cause death. Plasma renin was analyzed as a continuous variable using restricted cubic splines. A 6-month landmark analysis assessed treatment effects of MRA as opposed to baseline renin-angiotensin system inhibitors. Results: Continuous renin level showed a U-shaped association with MACE, with the lowest risk at 1.17ng/mL/h. In categorical analyses, low renin (<0.3 ng/mL/h; adjusted hazard ratio [HR]=1.29, 95% CI 1.15-1.45) and high renin (>3.0ng/mL/h; HR=1.19, 95% CI 1.06-1.33) were both associated with higher MACE risk. Initiation of MRA therapy after renin measurement was associated with a graded reduction in MACE risk where patients with low renin had the lowest risk (HR=0.75, 95%CI 0.60-0.92), and patients with high-renin had the highest risk (HR=1.41, 95%CI 1.03-1.94). In contrast, baseline use of renin-angiotensin system inhibitors was associated with a graded reduction in MACE risk where patients with high-renin had the lowest risk (HR=0.76, 95%CI 0.63-0.92) but those with low renin did not benefit (HR=0.87, 95%CI 0.72-1.04). Conclusions: Plasma renin activity may serve as a potential biomarker that integrates cardiovascular risk stratification and treatment selection in hypertension. Both suppressed and elevated renin were associated with increased cardiovascular risk, but the associated treatment patterns differed by renin phenotype. These findings support a renin-guided approach to hypertension care, in which MRA may be preferentially considered in low-renin states, whereas renin-angiotensin system inhibitors may be more beneficial in high-renin states. Prospective studies are warranted to determine whether renin-guided treatment improves long-term cardiovascular outcomes.